 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

For the last three days, A.I.dvisor has detected that ETNB's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

89bio (ETNB, $15.46) Aroon Indicator entered a Downtrend on September 29, 2023.

89bio (ETNB, $15.44) Aroon Indicator entered a Downtrend on September 28, 2023.

89bio (ETNB, $15.09) Aroon Indicator entered a Downtrend on September 27, 2023.

89bio (ETNB, $15.68) Aroon Indicator entered a Downtrend on September 26, 2023.

This is a signal that ETNB's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

89bio (ETNB, $15.63) RSI Indicator left the oversold zone on September 21, 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

89bio announces U.S. FDA granted BTD for pegozafermin

Supported by positive data in F2/F3 and F4 NASH patients from the ENLIVEN Phase 2b trial of pegozafermin Discussions with regulatory agencies regarding the NASH Phase 3 program planned for the...

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...

89bio to Participate in the 2023 Cantor Global Healthcare Conference

This indicator may be signaling that ETNB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

89bio (ETNB, $17.04) entered Downtrend as Momentum indicator drops below 0 level on Sep 18, 2023

89bio, Inc. (NASDAQ:ETNB  Get Free Report) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 6,290,000...

Short Interest in 89bio, Inc. (NASDAQ:ETNB) Decreases By 28.4%

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Watchers	1,447
52-Wk Low	$5.24
52-Wk High	$22.93

Market Cap	$1.17B
Volume (M)	2.46M
52-Wk High	$22.93
52-Wk Low	$5.24

ETNB 89bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals